EPS Rolls Out Biopharma Growth Metrics

US-based Executive Planning Service (EPS), which provides global brand planning and measurement services for clients in the biopharmaceutical industry, has launched a syndicated brand performance service for life science executives.

EPS uses a combination of primary and secondary data and expert opinion to help firms identify market opportunities and evaluate market scenarios - including market landscape shifts, customer behavior changes, promotion and media effects, and competitor responses - and then choose appropriate investments that deliver quantified commercial outcomes.

The new 'Predictive Growth Metrics' service analyzes market gaps, provides intelligence on a product's performance, and measures and predicts current and future brand share using sales data and predictive forecasting. It has been developed to help clients prioritize activity and allocate global resources for market access pricing strategies, R&D clinical trials investments, and key opinion leader management.

CEO and founder Steven Mackey (pictured) comments: 'As a holistic syndicated service, Predictive Growth Metrics is now a primary source of competitive intelligence for the full healthcare landscape and can offer clients a consistent view across markets. We are working to get the excesses out of the system; speeding up client decision making at a critical time when the industry is trying to do more with fewer resources.'

Web site: www.executiveplanningservice.com .